Background & Aims In 2017, the World Health Organization (WHO) designated
clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and …

Background Helicobacter pylori is one of the most prevalent global pathogens and can lead
to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and …

Objective Our aim was to prospectively assess the antibiotic resistance rates in Helicobacter
pylori strains in Europe in 2018 and to study the link between antibiotic consumption in the …

Important progress has been made in the management of Helicobacter pylori infection and
in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role …

Background So far, a comprehensive systematic review and meta-analysis has not been
done of the prevalence of primary antibiotic resistance in Helicobacter pylori in the Asia …

Background We previously showed rising primary antibiotic resistance of Helicobacter pylori
during 1990–2015 in the Asia-Pacific region. However, whether primary antibiotic resistance …

Clarithromycin is a macrolide antibiotic widely used for eradication of Helicobacter pylori
infection, and thus resistance to this antibiotic is a major cause of treatment failure. Here, we …

Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-
day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly …

Background Although 7-day triple therapy, consisting of vonoprazan, amoxicillin (AMO), and
clarithromycin (CLA), is recommended for Helicobacter pylori (H. pylori) eradication in …

Helicobacter pylori (H. pylori) antimicrobial resistance is an urgent, global issue. In 2017, the
World Health Organization designated clarithromycin-resistant H. pylori as a high priority …